• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

UCLA, partners get $11M to develop stroke-prevention programs for minority populations
UCLA researchers and their partners across Los Angeles County have been awarded an $11 million federal grant to fund research on community-based interventions aimed at reducing the higher rates of stroke and death from stroke among disadvantaged Hispanics, African Americans and Asian Americans.   Research has shown that stroke risk can be substantially lowered by increasing physical activity, controlling blood pressure, adopting a healthy diet, quitting smoking, lowering cholesterol and, for certain individuals, taking medication like aspirin.   However, the underserved populations targeted by this research progr...
Source: UCLA Newsroom: Health Sciences - May 1, 2013 Category: Universities & Medical Training Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news